J. Humphreys

发表

IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES

J. Polli, J. Rautio, J. Humphreys, 2006, Drug Metabolism and Disposition.

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

Vijay K Gombar, Joseph W Polli, J. Polli, 2004, Journal of pharmaceutical sciences.

Rational use of in vitro P-glycoprotein assays in drug discovery.

J. Polli, L. Huang, J. Humphreys, 2001, The Journal of pharmacology and experimental therapeutics.

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells.

K. Brouwer, J. Polli, G. M. Pollack, 1999, Biochemical pharmacology.

The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.

Kelly H. Jordan, Joseph W Polli, Giovanni Vitulli, 2004, Drug metabolism and disposition: the biological fate of chemicals.

MULTIPLE MECHANISMS ARE INVOLVED IN THE BILIARY EXCRETION OF ACETAMINOPHEN SULFATE IN THE RAT: ROLE OF MRP2 AND BCRP1

K. Brouwer, K. Hoffmaster, J. Polli, 2005, Drug Metabolism and Disposition.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

A. S. Gross, J. Polli, E. Lee, 2010, Journal of pharmaceutical sciences.

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies

J. Polli, M. Reese, J. Humphreys, 2012, Drug Metabolism and Disposition.

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.

J. Miller, J. Humphreys, T. Blumenkopf, 1999, Bioconjugate chemistry.

Benzoquinazoline Inhibitor of Thymidylate Synthase Biochemical and Cellular Pharmacology of 1843 U 89 , a Novel Updated

Pendergast, Kathleen, J. Humphreys, 2006 .

Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in VivoStable Prodrugs of Methotrexate*

John Miller, J. Humphreys, T. Blumenkopf, 1997, The Journal of Biological Chemistry.

The Role of Efflux and Uptake Transporters in Lapatinib ( Tykerb , GW 572016 ) Disposition and Drug Interactions

Kelly A. Harmon, J. Polli, Lisa St. John-Williams, 2008 .

An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer

A. Whitehead, B. Rowlands, J. Humphreys, 2012, Pancreas.

Comparison of cadmium cytotoxicity in human versus rat nasal epithelial cells in vitro.

V. Steele, D. Morgan, G. Hatch, 1990, Toxicology in vitro : an international journal published in association with BIBRA.

A vaccination strategy for the long-term suppression of androgens in advanced prostate cancer.

J. Humphreys, R. Parkinson, M. Simms, 2004, European urology.

Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer

J. Humphreys, M. Simms, M. Bishop, 2000, British Journal of Cancer.

Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid.

R. Ferone, J. Humphreys, R. Kisliuk, 1991, Journal of medicinal chemistry.

Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones.

R. Ferone, J. Humphreys, J. Kelly, 1993, Journal of medicinal chemistry.

In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

Kelly A. Harmon, James D. Clarke, J. Polli, 2013, Drug Metabolism and Disposition.

Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.

R. Ferone, J. Humphreys, Gary K. Smith, 1993, Cancer research.

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam

J. Polli, M. Reese, J. Humphreys, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

B. Wynne, J. Humphreys, G. Bowers, 2016, Journal of acquired immune deficiency syndromes.

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.

Nipa Shah, Joseph W Polli, J. Polli, 2009, Molecular pharmaceutics.

ENHANCEMENT OF ANCHORAGE-INDEPENDENT SURVIVAL OF RETROVIRUS-INFECTED FISCHER RAT EMBRYO CELLS FOR DETERMINING THE CARCINOGENIC POTENTIAL OF CHEMICAL AND PHYSICAL AGENTS

E. Hays, W. Suk, J. Humphreys, 1985 .

The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

Kelly A. Harmon, J. Polli, Lisa St. John-Williams, 2008, Drug Metabolism and Disposition.

Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs

Stephen A. Wring, Joseph W. Polli, Kimberly K. Adkison, 2002, Journal of Pharmacology and Experimental Therapeutics.

A phase II study of G17DT in gastric carcinoma.

S. Watson, A. McKenzie, J. Humphreys, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat

Kim L. R. Brouwer, K. Brouwer, K. Hoffmaster, 2006, Journal of Pharmacology and Experimental Therapeutics.

P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.

Kelly H. Jordan, Joseph W Polli, J. Polli, 2003, Journal of pharmaceutical sciences.

Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor

Joseph W. Polli, J. Polli, J. Humphreys, 1999, Pharmaceutical Research.

In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates.

J. Polli, T. Tippin, J. Humphreys, 2004, Journal of pharmaceutical sciences.

Influence of Passive Permeability on Apparent P-glycoprotein Kinetics

James E. Polli, Stephen A. Wring, Joseph W. Polli, 2000, Pharmaceutical Research.

Kelly A. Harmon, J. Polli, Lisa St. John-Williams, 2008, Drug Metabolism and Disposition.

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance and Ketoconazole Interaction Studies.

J. Polli, J. Humphreys, R. Dobbins, 2012 .